Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2012

View Archived Issues

New antibody could facilitate early diagnosis of neurological disorders

Galectin Therapeutics prepares to advance lead candidate for NASH

DSMBs recommend continuation of ongoing RetinoStat and StarGen trials

NIH designs recombinant oncolytic immunotoxins that may be given at high doses

Investigation reveals new potential target for treating schizophrenia

Merck & Co. divulges novel candidate antihypertensives

Abbott presents new ALK inhibitors

U.S. university patents novel anticancer products

Adynxx completes enrollment in trial of lead pain therapeutic

Alimera Sciences to resubmit Iluvien NDA

Novel FFA2 receptor agonists reported by Galapagos

Ferrer files IND for topical antifungal agent

NICE guideline aims to improve outcome of lower limb peripheral arterial disease

Research at Merck & Co. yields new MR antagonists

NICE issues final guideline on assessing fragility fracture risk in adults

Novel bacterial OMV-based vaccines developed in U.S.

VitroGro CE mark approval application referred to U.K.'s MHRA

Ganitumab studies halted

New ROR1-binding antibodies designed in California

Recruitment complete in phase III OMS-103HP trial

Final data reported from phase II trial of nasal spray for binge eating disorder

Acetylon Pharmaceuticals begins phase Ib trials in multiple myeloma

Dicerna earns milestone payment in oncology collaboration

MJFF issues grant for potential rescue therapy for Parkinson's disease

SPA agreement reached for third phase III trial of oral laquinimod in RRMS

MEI Pharma enters agreement to acquire rights to oral HDAC inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...